Lrig1 antibody (AA 79-906)

Catalog No. ABIN7876806

The Rabbit Polyclonal anti-Lrig1 antibody is suitable to detect Lrig1 in samples from Human. It has been validated for WB and ELISA.

Quick Overview for Lrig1 antibody (AA 79-906) (ABIN7876806)

Target: Lrig1 (Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This Lrig1 antibody is un-conjugated

Application: Western Blotting (WB), ELISA

Product Details anti-Lrig1 Antibody

Binding Specificity: AA 79-906

Purpose: LRIG1 Antibody / Leucine-rich repeats and immunoglobulin-like domains protein 1

Purification: Immunogen affinity purified

Immunogen: E.coli-derived human LRIG1 recombinant protein (Position: K79-E906) was used as the immunogen for the LRIG1 antibody.

Isotype: IgG

Application Details

Application Notes: Optimal dilution of the LRIG1 antibody should be determined by the researcher.

Restrictions: For Research Use only

Handling

Format: Lyophilized

Reconstitution: Adding 0.2 mL of distilled water will yield a concentration of 500 μg/mL

Buffer: Each vial contains 4 mg Trehalose, 0.9 mg NaCl, 0.2 mg Na2HPO4.

Storage: 4 °C,-20 °C

Storage Comment: After reconstitution, the LRIG1 antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.

Target Details for Lrig1

Target: Lrig1 (Leucine-Rich Repeats and Immunoglobulin-Like Domains 1 (Lrig1))

Alternative Name: LRIG1

Background: LRIG1 antibody detects Leucine-rich repeats and immunoglobulin-like domains protein 1, a transmembrane protein that regulates growth factor receptor signaling and functions as a tumor suppressor. Encoded by the LRIG1 gene on chromosome 3p14.1, this protein contains multiple extracellular leucine-rich repeats and three immunoglobulin-like domains that enable binding to receptor tyrosine kinases, including members of the epidermal growth factor receptor (EGFR) family. LRIG1 promotes receptor ubiquitination and degradation, attenuating signaling that drives proliferation and differentiation.

LRIG1 localizes primarily to the plasma membrane but can also be detected in intracellular vesicles and the nucleus. It negatively regulates EGFR, ERBB2, and ERBB3 signaling by recruiting E3 ubiquitin ligases such as CBL to target receptors for degradation. In addition to receptor regulation, LRIG1 functions as a stem cell marker in epithelial tissues, maintaining quiescence and tissue renewal capacity. In the intestine and skin, LRIG1 marks long-lived stem cells essential for tissue homeostasis.

The LRIG1 antibody is widely used in cancer biology, stem cell, and developmental research to study growth factor receptor regulation, cell differentiation, and tumor suppression. Western blot analysis identifies a 120-150 kilodalton band corresponding to LRIG1, while immunohistochemistry reveals membrane and cytoplasmic staining in epithelial and neural tissues. This antibody supports investigations into receptor turnover, oncogenic signaling, and epithelial regeneration.

Loss or downregulation of LRIG1 is associated with tumor progression in gliomas, breast, and colorectal cancers due to hyperactivation of growth factor signaling. Conversely, overexpression suppresses tumor growth by dampening EGFR pathway activity. The LRIG1 antibody provides a reliable tool for studying receptor regulation, epithelial biology, and cancer suppression. NSJ Bioreagents offers this antibody validated for its applications, ensuring consistent detection in growth signaling research.

UniProt: Q96JA1